{"id":10261,"date":"2026-07-15T11:43:36","date_gmt":"2026-07-15T09:43:36","guid":{"rendered":"https:\/\/cleanpeptides.eu\/tesamorelin-doseringsguide\/"},"modified":"2026-07-15T11:43:36","modified_gmt":"2026-07-15T09:43:36","slug":"tesamorelin-doseringsguide","status":"publish","type":"page","link":"https:\/\/cleanpeptides.eu\/da\/tesamorelin-doseringsguide\/","title":{"rendered":"Tesamorelin doseringsguide"},"content":{"rendered":"<p><em>Kun til forskningsform\u00e5l \u2014 ikke beregnet til menneskelig brug. Clean Peptides giver ingen r\u00e5dgivning om dosering eller brug. Denne guide samler produktinformation og uafh\u00e6ngigt undervisningsmateriale som forskningsreference; den udg\u00f8r ikke l\u00e6gelig r\u00e5dgivning.<\/em><\/p>\n<h2>Hvad er Tesamorelin?<\/h2>\n<p>Tesamorelin (handelsnavn Egrifta) er en syntetisk analog af GHRH \u2014 de fulde 44 aminosyrer af human GHRH (1-44) med en trans-3-hexensyre N-terminal modifikation for stabilitet. Det fik FDA-godkendelse i 2010 til at reducere overskydende bugfedt (lipodystrofi) hos HIV-inficerede patienter. I mods\u00e6tning til eksogent HGH stimulerer det en pulserende GH-frigivelse, mens somatostatin-feedbacksl\u00f8jfen bevares, hvilket reducerer risikoen for suprafysiologisk GH\/IGF-1. Fors\u00f8g viste en reduktion p\u00e5 15-18 % af det viscerale fedtv\u00e6v over 26 uger.<\/p>\n<h2>N\u00f8gleegenskaber<\/h2>\n<ul>\n<li>GHRH-analog (44 aminosyrer) \u2014 den eneste FDA-godkendte GHRH-analog.<\/li>\n<li>FDA-godkendt (2010) \u2014 til HIV-associeret lipodystrofi (Egrifta \/ Egrifta SV).<\/li>\n<li>Pulserende GH-frigivelse \u2014 bevarer somatostatin-feedbacksl\u00f8jfen.<\/li>\n<li>Specificitet for visceralt fedt \u2014 15\u201318 % VAT-reduktion over 26 uger; minimal effekt p\u00e5 underhudsfedt.<\/li>\n<li>Kognitivt potentiale \u2014 STAY-studiet (2019) viste bevaret kognition hos \u00e6ldre HIV-positive.<\/li>\n<\/ul>\n<h2>S\u00e5dan fastl\u00e6gges doseringen<\/h2>\n<p>Us\u00e6dvanligt veletableret \u2014 fuld FDA-godkendelsesproces. Dosen p\u00e5 2 mg dagligt blev valgt i fase II og bekr\u00e6ftet i fase III-RCT&#8217;er (800 patienter, Falutz et al. 2007, 2010). VAT-reduktion p\u00e5 15\u201318 % vs placebo ved 26 uger. STAY-studiet: 12-m\u00e5neders kognitiv RCT. Evidensniveau: st\u00e6rkt.<\/p>\n<h2>Standarddosering<\/h2>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Protokol<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Dosis<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Hyppighed<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Noter<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">FDA-godkendt (Egrifta)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2 mg SC<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">En gang dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Fase III-fors\u00f8gsdosis, endepunkt ved 26 uger<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Standard off-label<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2 mg SC<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">En gang dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Kropssammens\u00e6tning \/ anti-aldring, injektion om aftenen<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Konservativ<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1 mg SC<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">En gang dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">F\u00e6rre kliniske data ved denne dosis<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">5 on \/ 2 off (f\u00e6llesskab)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2 mg SC<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">5 dage\/uge<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Forl\u00e6nger brug af h\u00e6tteglas, ikke unders\u00f8gt i fors\u00f8g<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<h2>Rekonstituering og dosering (med de medf\u00f8lgende 3 mL)<\/h2>\n<p>Hvert Clean Peptides-h\u00e6tteglas leveres med 3 mL bakteriostatisk vand (0,9 % benzylalkohol). Alle tal nedenfor foruds\u00e6tter rekonstituering med de fulde 3 mL. P\u00e5 en standard U-100-insulinspr\u00f8jte er 100 enheder = 1 mL.<\/p>\n<p><strong>Hurtig formel:<\/strong> koncentration = h\u00e6tteglassets styrke \u00f7 3 mL; enheder der skal tr\u00e6kkes = dosis (mg) \u00d7 300 \u00f7 h\u00e6tteglassets styrke (mg).<\/p>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">H\u00e6tteglas (Clean Peptides)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Koncentration<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">1 mg<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">2 mg<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">10 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">3,33 mg\/mL<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">30 u<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">60 u<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<p>Opbevar det rekonstituerede produkt i k\u00f8leskab (2\u20138 \u00b0C) og brug det inden for 28-30 dage.<\/p>\n<h2>Dosering efter m\u00e5l<\/h2>\n<ul>\n<li><strong>Reduktion af visceralt fedt (FDA-indikation):<\/strong> 2 mg SC\/dag, mindst 26 uger. CT\/DEXA ved baseline og 26 uger; IGF-1 ved baseline, 8 uger, 26 uger. Om aftenen\/ved sengetid, fastende 1\u20132 t.<\/li>\n<li><strong>Kropssammens\u00e6tning og anti-aldring (off-label):<\/strong> 2 mg SC\/dag, om aftenen\/ved sengetid, fastende, 12\u201326 uger og derefter pause.<\/li>\n<li><strong>Kognitiv st\u00f8tte:<\/strong> 2 mg SC\/dag, 12 m\u00e5neder (STAY-studiet); data begr\u00e6nset til HIV-positiv population.<\/li>\n<\/ul>\n<h2>Injektionsguide<\/h2>\n<p>Vask h\u00e6nderne og g\u00f8r en ren arbejdsflade klar. Aft\u00f8r h\u00e6tteglassets prop og lad den luftt\u00f8rre. Tr\u00e6k dosen op (typisk hele h\u00e6tteglasset til 2 mg) og bank boblerne ud. V\u00e6lg maven (FDA-godkendt sted), 2\u20133 cm fra navlen, undg\u00e5 arv\u00e6v. Rens stedet og lad det t\u00f8rre. Injicer i en knebet fold ved 45\u00b0. Bortskaf i en kanylebeholder. Optimal timing: om aftenen\/ved sengetid (synergi med den natlige GH-b\u00f8lge), fastende 1\u20132 t. Konsekvent daglig dosering, skift sted inden for maven.<\/p>\n<h2>Kurvarighed og timing<\/h2>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Protokol<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Varighed<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Noter<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Standard (FDA-fors\u00f8g)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">26 uger dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Fase III prim\u00e6rt endepunkt<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Udvidet<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">52 uger dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Bevaret gavn, l\u00e6ngste unders\u00f8gte<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Cyklisk<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">26 uger on, 8\u201312 uger off, gentag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Hypofyse-restitution, omkostningsstyring<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">5 on \/ 2 off ugentligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">L\u00f8bende, 5 dage\/uge<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Reducerer omkostningen 30 %, ikke unders\u00f8gt<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<p>Visceralt fedt genophobes efter oph\u00f8r; IGF-1 normaliseres inden for uger. Ingen PCT n\u00f8dvendig (hypofysen undertrykkes ikke).<\/p>\n<h2>Kombinationer (stacking)<\/h2>\n<p><strong>Tesamorelin + Ipamorelin<\/strong> \u2014 GHRH + GHRP-synergi (guldstandard): Tesamorelin 2 mg SC om aftenen + Ipamorelin 200\u2013300 mcg SC ved sengetid, fastende. Adskilte receptorveje \u2192 synergistisk GH-respons. Andre stacks: + AOD-9604 (direkte lipolyse, morgen fastende) eller + BPC-157 (GH-optimering + v\u00e6vsreparation).<\/p>\n<h2>Sikkerhed, bivirkninger og kontraindikationer<\/h2>\n<p><strong>Kr\u00e6ftscreening p\u00e5kr\u00e6vet<\/strong> \u2014 GH\/IGF-1 fremmer cellev\u00e6kst; aktiv malignitet er en FDA-m\u00e6rket kontraindikation. Gennemf\u00f8r aldersrelevant screening f\u00f8r start.<\/p>\n<p>Almindelige (fase III): reaktioner ved injektionsstedet (13 %), artralgi (13 %), perifert \u00f8dem, myalgi. Mindre almindelige: hyperglyk\u00e6mi\/insulinresistens, karpaltunnelsyndrom, par\u00e6stesi, kvalme.<\/p>\n<p><strong>Kontraindikationer:<\/strong> aktiv malignitet; forstyrret hypothalamus-hypofyse-akse; graviditet (kategori X); overf\u00f8lsomhed (inkl. mannitol); ukontrolleret diabetes.<\/p>\n<p><strong>Monitorering:<\/strong> IGF-1 (baseline, 8 uger, 26 uger), fasteblodsukker og HbA1c, kr\u00e6ftscreening, thyroideapanel, lipider. M\u00e5 ikke kombineres med eksogent HGH. Receptpligtig medicin; WADA-forbudt.<\/p>\n<h2>Almindelige fejl<\/h2>\n<ul>\n<li>At injicere efter et m\u00e5ltid i stedet for fastende.<\/li>\n<li>At forvente HGH-niveau-resultater af en GHRH-analog.<\/li>\n<li>At stoppe f\u00f8r 26 uger.<\/li>\n<li>At springe IGF-1-monitorering over.<\/li>\n<li>At kombinere med eksogent HGH.<\/li>\n<li>At starte uden kr\u00e6ftscreening.<\/li>\n<li>Inkonsekvent daglig dosering.<\/li>\n<li>At bruge Egrifta (sterilt vand) i mere end 24 timer.<\/li>\n<\/ul>\n<h2>Vigtigste pointer<\/h2>\n<ul>\n<li>Den eneste FDA-godkendte GHRH-analog; den st\u00e6rkeste kliniske evidens af alle GH-peptider.<\/li>\n<li>Fast 2 mg SC en gang dagligt (ingen v\u00e6gtbaseret justering).<\/li>\n<li>Pulserende GH-frigivelse, der bevarer feedback; 15\u201318 % reduktion af visceralt fedt over 26 uger.<\/li>\n<li>Injicer ved sengetid, fastende. Bedste stak: Tesamorelin + Ipamorelin.<\/li>\n<li>Kr\u00e6ftscreening p\u00e5kr\u00e6vet; overv\u00e5g IGF-1; kombin\u00e9r ikke med HGH.<\/li>\n<\/ul>\n<h2>Download og relaterede ressourcer<\/h2>\n<p><a href=\"https:\/\/cleanpeptides.eu\/wp-content\/uploads\/2026\/07\/11-Tesamorelin-Dosage-Guide-Clean-Peptides.pdf\">\ud83d\udcc4 Download den fulde PDF-guide<\/a><\/p>\n<p><a href=\"https:\/\/cleanpeptides.eu\/product\/tesamorelin-10-mg\/\">Tesamorelin 10 mg<\/a> \u00b7 <a href=\"https:\/\/cleanpeptides.eu\/ipamorelin-dosage-guide\/\">Ipamorelin doseringsguide<\/a> \u00b7 <a href=\"https:\/\/cleanpeptides.eu\/mots-c-dosage-guide\/\">MOTS-c doseringsguide<\/a><\/p>\n<h2>Referencer<\/h2>\n<ol>\n<li>Falutz J, et al. \u00abTesamorelin on visceral fat reduction in HIV-infected patients.\u00bb N Engl J Med. 2007;357:2359-2370.<\/li>\n<li>Falutz J, et al. \u00abMetabolic effects of a GH-releasing factor in patients with HIV.\u00bb J Clin Endocrinol Metab. 2010;95(9):4291-4304.<\/li>\n<li>Stanley TL, et al. \u00abTesamorelin on visceral and liver fat in HIV patients.\u00bb JAMA. 2014;312(4):380-389.<\/li>\n<li>Stanley TL, et al. \u00abTesamorelin effects on neuropsychological function in HIV older adults.\u00bb AIDS. 2019;33(7):1179-1188.<\/li>\n<li>Dhillon S. \u00abTesamorelin: a review in HIV-associated lipodystrophy.\u00bb Drugs. 2011;71(8):1071-1091.<\/li>\n<\/ol>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div> \n","protected":false},"excerpt":{"rendered":"<p>Kun til forskningsform\u00e5l \u2014 ikke beregnet til menneskelig brug. Clean Peptides giver ingen r\u00e5dgivning om dosering eller brug. Denne guide [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-10261","page","type-page","status-publish","hentry"],"_hostinger_reach_plugin_has_subscription_block":false,"_hostinger_reach_plugin_is_elementor":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/comments?post=10261"}],"version-history":[{"count":0,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10261\/revisions"}],"wp:attachment":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/media?parent=10261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}